newwin
Luciann Nguyen
Settings
← Accounts
biotech

Gustave Roussy, Cancer Campus, Grand Paris

48
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Gustave Roussy, Cancer Campus, Grand Paris

New trial — Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

New trialNCT05631249
48/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 2 trial NCT05631249 posted by Gustave Roussy, Cancer Campus, Grand Paris: "Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 488 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT05631249
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
phase 2
ctDNA